Navigation Links
Commercial Launch of Lexiscan(TM) (Regadenoson) Injection Triggers $10 Million Milestone Payment from TPG-Axon Capital to CV Therapeutics
Date:6/24/2008

xecutive officer. "Our partners at Astellas are the market leaders in the MPI market and are very well positioned for commercial success."

CV Therapeutics owns the rights for regadenoson outside of North America and currently expects to submit a marketing authorization application for the product to the European Medicines Agency by the end of 2008.

Astellas Pharma US, Inc. / CV Therapeutics Inc. Collaboration

Under a license and collaboration agreement providing Astellas with exclusive North American rights to Lexiscan(TM) (regadenoson) injection, CV Therapeutics completed the development program and Astellas is responsible for all commercial activities for the product in North America. Under the arrangement, Astellas paid CV Therapeutics a $7 million milestone upon submission of the new drug application to the FDA, and a $12 million milestone in April 2008. Astellas also reimburses CV Therapeutics for 75 percent of development costs. CV Therapeutics will receive a royalty on product sales of Lexiscan(TM) (regadenoson) injection, and may receive a royalty on another Astellas product.

About Lexiscan(TM) (regadenoson) injection

Lexiscan(TM) is an A2A adenosine receptor agonist approved for use as a pharmacologic stress agent in radionuclide MPI studies in patients unable to undergo adequate exercise stress. Lexiscan(TM) was designed to produce coronary vasodilation and increase coronary blood flow by activation of the A2A adenosine receptor. Lexiscan(TM) is administered as a rapid bolus (approximately 10 seconds) with no dose adjustment required for body weight. Lexiscan(TM) should not be administered to patients with second- or third-degree AV block or sinus node dysfunction who do not have a functioning artificial pacemaker. Adenosine receptor agonists, including Lexiscan(TM), induce arterial vasodilation and hypotension. The risk of serious hypotension may be higher in patients with cardiac or cerebrovascular insufficiency. Comple
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. SAFC Expands European Commercial Manufacturing and Storage Capacities With $10 Million Investment
2. Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases
3. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
4. ADVENTRX Appoints Vice President of Commercialization
5. Pharmaceutical Product Launch: Commercially Focused R&D Increases Drugs Market Potential
6. Accera, Inc. Names William T. Poncy Vice President of Commercial Development
7. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
8. Genencor Launches First Ever Commercial Enzyme Product for Cellulosic Ethanol
9. Affymax(R) and Takeda Recognized for Innovative Global Agreement to Develop and Commercialize Hematide(TM) for Anemia
10. Neurocrine Biosciences and Dainippon Sumitomo Pharma (DSP) Announce Agreement to Develop and Commercialize Indiplon in Japan
11. Product Development Timelines and Commercialization Strategy Are Focus of New Group at Premier Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 2014 ITRA Global, one of the ... commercial real estate, has further expanded its global reach ... and Brisbane, Western Australia, reports Mylinda Vick, CCIM, Chairman ... ITRA Global / ACORPP (Australian Corporate Property and Projects) ... providing property services to a wide range of clients ...
(Date:12/19/2014)... December 19, 2014 Charm Sciences is ... for the Detection of Aflatoxin M1 in raw commingled ... independent third party validation. The peer reviewed report of ... the Institute for Agricultural and Fisheries Research (ILVO-T&V) has ... , Aflatoxin B1, the most toxic aflatoxin and a ...
(Date:12/19/2014)... , Dec. 19, 2014  Roche (SIX: RO, ROG; ... Technologies, Inc. (Bina), a privately held company based ... USA. Bina provides a big data platform for ... (NGS) data. Bina,s proprietary on-market Genomic Management Solution, ... researchers to perform fast and scalable analyses to ...
(Date:12/19/2014)... 19, 2014 Research and Markets ... the "Technology Innovations in Smart Fabrics (Technical ... http://photos.prnewswire.com/prnh/20130307/600769 The ... offers a detailed assessment on technological advancements and ... 1. The Smart Fabrics market ...
Breaking Biology Technology:ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2Roche acquires Bina Technologies and enters the genomic informatics market 2Roche acquires Bina Technologies and enters the genomic informatics market 3Technology Innovations in Smart Fabrics (Technical Insights) 2
... jobs Berbee ranks highly in Microsoft partner program ... Wausau police nab suspected wireless hacker ... parent company of SBC Wisconsin, will cut about 10,000 jobs by the ... According to spokesperson Howard Riefs, SBC does not know how many of ...
... we took a look at the PricewaterhouseCoopers quarterly report on venture ... As part of this analysis, we look at VC activity in ... region. , ,This week, lets take a look at VC ... any trends over time. Ready? Here we go! , , ...
... Trying to guess Tommy Thompsons next career move is like attempting ... see through the glass and make an educated guess but ... important disclaimer aside, here are some long-shot predictions about what Wisconsins ... of the U.S. Department of Health and Human Services. For those ...
Cached Biology Technology:Tech Digest: whats moving in the Midwest (11/8/04) 2Though VC investing is down, reloading on new funds is rising 2Though VC investing is down, reloading on new funds is rising 3Could Tommy Thompsons next stop be Transportation, Homeland Security, or the private sector? 2Could Tommy Thompsons next stop be Transportation, Homeland Security, or the private sector? 3
(Date:12/11/2014)... 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of ... 2015-2019"  report to their offering. ... advances in technology. With continuous advances in technology, ... the latest standard that meets the needs and ...
(Date:12/11/2014)... 2014  Data Sciences International (DSI), the global ... new series of digital telemetry implants to meet ... series, part of the PhysioTel™ Digital platform, was ... physiologic data when incorporating functional endpoints into repeat-dose ... toxicology studies has evolved from short ECG strips ...
(Date:12/10/2014)...  Wake Forest Baptist Medical Center today announced plans for ... Medicine. Funding for this $50 million capital project is ... publicly launched next summer. The medical ... series R.J. Reynolds Tobacco Company complex, adjacent to 525@vine ... with plans to be ready to welcome medical students ...
Breaking Biology News(10 mins):Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... in the park can dramatically change natural ecosystems, according ... University of California, Berkeley. These findings could have important ... parks in the San Francisco Bay Area that allow ... with nearby nature reserves that allow no public access. ...
... Memorial Hospital of Chicago announced today that it has ... its Adult Phenylketonuria (PKU) Outreach Education Project. The ... PKU patients who are no longer being treated at ... education about recent developments in the management and treatment ...
... Researchers from four leading cancer centers have confirmed that ... to predict which lung cancer patients will have the worst ... that would help determine who needs more aggressive treatment. ... Nature Medicine . The researchers looked at ...
Cached Biology News:Outdoor enthusiasts scaring off native carnivores in parks 2Outdoor enthusiasts scaring off native carnivores in parks 3Outdoor enthusiasts scaring off native carnivores in parks 4Children's Memorial Hospital of Chicago receives a grant from BioMarin to support adult PKU outreach 2Gene panel predicts lung cancer survival, study finds 2
Rabbit polyclonal to Vitronectin ( Abpromise for all tested applications). Antigen: Full length native Vitronectin (Cow) Entrez Gene ID: 7448 Swiss Protein ID: P04004...
... Competitor Assay Kits are ideal for studying ... PolarScreen GR Competitor Assay Kits contain partially ... one of the following proprietary fluorescent glucocorticoid ... Red (red assay kit), or GS Far ...
... to PRMT5 Arginine methylation is an ... recently been linked to protein activity. At ... been identified in mammalian cells. These enzymes ... functions by methylation of key proteins in ...
... coli Biotinylation Kit, Plasmid is designed for use ... expression kits. (Cat. No. 3 186 148, 3 ... vectors for the easy introduction of a C- ... can be enzymatically mono-biotinylated by E. coli biotin ...
Biology Products: